Alnylam Pharmaceuticals, Inc.
ALNY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001178670
No open-market purchases or sales by Alnylam Pharmaceuticals, Inc. insiders were filed in the last 90 days; 794 institutions reported holding it in 13F filings for Q2 2026, worth $40.1B in total; no superinvestor holds it.
Holders of 5% or more of ALNY
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Alnylam Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 12.80%16.8M shares | – | Nov 5, 20251 filing | Nov 5, 2025 | SEC |
| Capital Research Global Investors | 13G | 5.40%6.97M shares | New | Feb 13, 20251 filing | Feb 13, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
4 Schedule 13D and 13G filings on Alnylam Pharmaceuticals, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 20263:24 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −10.03 ppfrom 10.03%Below 5% | Mar 13, 2026 | SEC |
| Nov 5, 202511:26 AM ET | FMR LLCand 1 other | 13G/A | 12.80%16.8M shares | – | Sep 30, 2025 | SEC |
| Apr 7, 202511:51 AM ET | Vanguard Group Inc | 13G/A | 10.03%13.1M shares | – | Mar 31, 2025 | SEC |
| Feb 13, 20252:14 PM ET | Capital Research Global Investors | 13G | 5.40%6.97M shares | New | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Alnylam Pharmaceuticals, Inc. shares.
No Form 144 notices for Alnylam Pharmaceuticals, Inc. are on file.